MedTrace Logo

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 594

Last updated 2026-05-22

No results posted yet for this study

Summary

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.

The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG

Prednisolone

Oral administration or IV infusion

BIOLOGICAL

Polatuzumab vedotin

IV infusion

DRUG

Rescue Medication

Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).

BIOLOGICAL

Rituximab Biosimilar

IV infusion

DRUG

Prednisone

Oral administration or IV infusion

BIOLOGICAL

Zilovertamab vedotin

IV infusion

BIOLOGICAL

Rituximab

IV infusion

DRUG

Cyclophosphamide

IV infusion

DRUG

Doxorubicin

IV infusion

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-11
Primary Completion
2027-12-13
Completion
2032-12-16
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Germany
  • Ireland
  • Israel
  • Italy
  • Japan
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06890884 on ClinicalTrials.gov